Global Pulmonary Embolism Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 1.65 Billion |
 Market Size (Forecast Year) |
USD 3.12 Billion |
 CAGR |
% |
| Major Markets Players |
>全球肺栓塞市场，按症状（呼吸急促、胸痛、咳嗽、心律不齐、头晕、发烧、发绀等）、诊断（胸部 X 光、心电图、核磁共振、 CT 扫描、肺血管造影、静脉造影、静脉超声、 D-二聚体测试等）、治疗（药物、机械设备、手术等）、最终用户（医院、专科诊所、家庭护理等）、分销渠道（医院药房、零售药房、网上药房等）– 行业趋势和预测到 2030 年。
肺栓塞市场分析和规模
近年来，预计全球肺栓塞市场将在 2023-2030 年预测期内快速增长。全球肺栓塞市场主要受肺栓塞疾病患病率上升的推动。对于老年人来说，肺部疾病可能是致命的。预计这一健康问题在世界老年人口中的患病率上升将在未来几年推动全球肺栓塞市场的销售。在诊断、医疗保健和医疗方面，不同的技术突破正在融入医疗保健行业。这种情况有利于全球肺栓塞市场的扩张。
Data Bridge Market Research 分析，全球肺栓塞市场在 2022 年为 16.5 亿美元，预计到 2030 年将达到 31.2 亿美元，预计在 2023-2030 年预测期内的复合年增长率为 8.30%。这表明市场价值。由于这种心脏病在世界老年人口中的患病率不断上升，“胸痛”在全球肺栓塞市场的症状部分中占据主导地位。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。
肺栓塞市场范围和细分
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021 (可定制为 2015-2020) |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
症状（呼吸困难、胸痛、咳嗽、心律不齐、头晕、发烧、发绀等）、诊断（胸部X光、心电图、核磁共振、CT扫描、肺血管造影、静脉造影、静脉超声、D-二聚体检测等）、治疗（药物、机械装置、手术等）、最终用户（医院、专科诊所、家庭护理等）、分销渠道（医院药房、零售药房、网上药房等） |
|
覆盖国家 |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Bristol-Myers Squibb Company (U.S.), Hikma Pharmaceuticals PLC (U.K.), Johnson & Johnson Private Limited (U.S.), Novartis AG (Switzerland), Boehringer Ingelheim International GmbH. (Germany), Fresenius Kabi AG (Germany), Bayer AG (Germany), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Baxter (U.S.), AstraZeneca (U.K.), Genentech Inc. (U.S.), Aspen Holdings (South Africa) |
|
Market Opportunities |
|
Market Definition
A pulmonary embolism is a blood clot in the lung that develops when a clot from another region of the body (usually the leg or arm) travels through the bloodstream and lodges in the lung's blood arteries. This reduces blood flow to the lungs, lowers oxygen levels in the lungs, and raises pulmonary artery blood pressure. PEs can cause heart or lung damage, as well as death, if not treated promptly.
Global Pulmonary Embolism Market Dynamics
Drivers
- Increasing Prevalence of Cancer
The global pulmonary embolism market is driven by an increase in prevalence of cancer. Patients who are receiving chemotherapy or who have a family history of the condition are at the greatest risk, which is expected to increase demand for the medications. The industry is expected to develop in response to the growing number of cancer patients. Cancer killed about 10 million people in 2020, according to the World Health Organization.
- Increasing Investment for Healthcare Infrastructure
Another significant factor influencing the growth rate of pulmonary embolism market is the rising healthcare expenditure which helps in improving its infrastructure.
- Rise in Smoking Addiction
Long-term smoking addiction is one of the leading causes of lung illnesses including pulmonary embolism. The stress levels of this population base have risen significantly as a result of growing urbanization, industrialization, and increased work pressure. This scenario is expected to result in an increase in smoking addiction, which would lead to greater sales potential in the worldwide global pulmonary embolism market.
Opportunity
- Increase in the Number of Research and Development Activities
Moreover, the market's growth is fuelled by an increase in the number of research and development activities. This will provide beneficial opportunities for the global pulmonary embolism market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate. Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the global pulmonary embolism market growth during the forecast period 2023-2030.
Restraint/Challenge
- Limited Awareness and Knowledge
There is a lack of awareness and knowledge about pulmonary embolism among healthcare professionals and the general population. This can result in delayed recognition of symptoms, leading to delays in seeking medical attention and appropriate treatment.
This global pulmonary embolism market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global pulmonary embolism market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In August 2021, Boston Scientific had announced the initiation of randomized controlled trial for the EkoSonic™ Endovascular System. In patients with PE and peripheral artery occlusions, the EKOS device employs ultrasound radiation in combination with a thrombolytic medication to break blood clots and restore blood flow. The EKOS system's ultrasound technology speeds up thrombolysis, or the breakup of a clot, reducing the time it takes to treat a patient and lowering the required thrombolytic dose, which can lead to better outcomes and a lower risk of bleeding.
Global Pulmonary Embolism Market Scope
The global pulmonary embolism market is segmented on the basis of symptoms, diagnosis, treatment, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Symptoms
- Shortness of Breath
- Chest Pain
- Cough
- Irregular Heartbeat
- Dizziness
- Fever
- Cyanosis
- Others
Diagnosis
- Chest X-Ray
- ECG
- MRI
- CT Scan
- Pulmonary Angiography
- Venography
- Venous Ultrasound
- D-Dimer Test
- Others
Treatment
- Medications
- Mechanical Devices
- Surgery
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Global Pulmonary Embolism Market Regional Analysis/Insights
The global pulmonary embolism market is analysed and market size insights and trends are provided by country, product, application, type and end-users as referenced above.
The countries covered in the global pulmonary embolism market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the global pulmonary embolism market because of the presence of major key players and growing prevalence of pulmonary embolism diseases in this region.
Asia-Pacific is expected to grow during the forecast period 2023-2030 due to rising number of geriatric people and increasing prevalence of pulmonary embolism in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
Global pulmonary embolism market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for global pulmonary embolism market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global pulmonary embolism market. The data is available for historic period 2015-2020.
Competitive Landscape and Global Pulmonary Embolism Market Share Analysis
The global pulmonary embolism market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to pulmonary embolism market
全球肺栓塞市场的一些主要参与者包括：
- 雅培（美国）
- F. Hoffmann-La Roche Ltd.（瑞士）
- Mylan NV（美国）
- Teva Pharmaceutical Industries Ltd.（耶路撒冷）
- 赛诺菲（法国）
- 辉瑞公司（美国）
- 葛兰素史克公司 (英国)
- 百时美施贵宝公司 (美国)
- Hikma Pharmaceuticals PLC（英国）
- 强生私人有限公司（美国）
- 诺华公司（瑞士）
- 勃林格殷格翰国际有限公司（德国）
- 费森尤斯卡比公司（德国）
- 拜耳公司（德国）
- 礼来公司 (美国)
- 默克公司（美国）
- 百特（美国）
- 阿斯利康（英国）
- 基因泰克公司（美国）
- 阿斯彭控股 (南非)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
